Molecular Pathways Molecular Pathways : BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
暂无分享,去创建一个
D. Fisher | H. Widlund | R. Haq | Rizwan Haq
[1] L. Cantley,et al. Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. , 2013, Molecular cell.
[2] L. Cantley,et al. Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma , 2013, Proceedings of the National Academy of Sciences.
[3] G. McArthur,et al. The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma , 2013, Clinical Cancer Research.
[4] T. Shlomi,et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence , 2013, Nature.
[5] F. Berrino,et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects , 2013, Oncogene.
[6] P. Puigserver,et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. , 2013, Cancer cell.
[7] Jun S. Song,et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.
[8] Jun S. Song,et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition , 2013, Proceedings of the National Academy of Sciences.
[9] Liu Wei,et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.
[10] Jonathan E. Shoag,et al. PGC-1 coactivators regulate MITF and the tanning response. , 2013, Molecular cell.
[11] J. Chesney,et al. Molecular Pathways: Regulation of Metabolism by RB , 2012, Clinical Cancer Research.
[12] J. Kirkwood,et al. Importance of glycolysis and oxidative phosphorylation in advanced melanoma , 2012, Molecular Cancer.
[13] J. Kirkwood,et al. Mitochondrial Respiration - An Important Therapeutic Target in Melanoma , 2012, PloS one.
[14] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[15] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[16] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[17] H. Horlings,et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. , 2012, Genes & development.
[18] P. Bahadoran,et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells , 2012, Oncogene.
[19] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[20] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[21] G. Giaever,et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. , 2011, Cancer cell.
[22] S. Gygi,et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. , 2011, Cancer cell.
[23] K. Brown,et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.
[24] S. Puig,et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.
[25] Jeff S. Jasper,et al. The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. , 2011, Cancer cell.
[26] D. Fisher,et al. Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF , 2011, Proceedings of the National Academy of Sciences.
[27] D. Fisher,et al. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[29] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[30] V. Mootha,et al. Nutrient‐sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis , 2011 .
[31] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[32] C. Wellbrock,et al. BRAF as therapeutic target in melanoma. , 2010, Biochemical pharmacology.
[33] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[34] M. Brown,et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. , 2010 .
[35] M. Berridge,et al. Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. , 2010, Rejuvenation research.
[36] I. Nagtegaal,et al. BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[37] L. Pollak. Moyamoya disease and moyamoya syndrome. , 2009, The New England journal of medicine.
[38] G. Merlino,et al. Uncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAFV600E , 2009, PloS one.
[39] L. Chin,et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. , 2009, Molecular cell.
[40] Julien Verrax,et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.
[41] Carlo Gambacorti-Passerini,et al. BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells , 2008, Molecular Cancer Research.
[42] Y. Yang,et al. Depletion of mitochondrial DNA by ethidium bromide treatment inhibits the proliferation and tumorigenesis of T47D human breast cancer cells. , 2007, Toxicology letters.
[43] Joanne M. Morrisey,et al. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum , 2007, Nature.
[44] G. Semenza,et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.
[45] N. Denko,et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.
[46] David P. Davis,et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. , 2006, Cancer research.
[47] R. Franklin,et al. Altered metabolism and mitochondrial genome in prostate cancer , 2006, Journal of Clinical Pathology.
[48] J. Shay,et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.
[49] T. Golub,et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.
[50] L. Zon,et al. BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma , 2005, Current Biology.
[51] C. Marshall,et al. B-RAF is a therapeutic target in melanoma , 2004, Oncogene.
[52] F. Haluska,et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.
[53] D. Tuveson,et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.
[54] H. Kusuhara,et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. , 2003, Molecular pharmacology.
[55] Yuri E Nikiforov,et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.
[56] Richard Wooster,et al. BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.
[57] Ronald A. DePinho,et al. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation , 2002, Nature.
[58] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[59] Sridhar Ramaswamy,et al. Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.
[60] M. Owen,et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.
[61] A. Koong,et al. Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.
[62] V. Ferrans,et al. Ras Proteins Induce Senescence by Altering the Intracellular Levels of Reactive Oxygen Species* , 1999, The Journal of Biological Chemistry.
[63] D. Woods,et al. Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.
[64] Richard A. Ashmun,et al. Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.
[65] S. Lowe,et al. Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.
[66] N. Jenkins,et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein , 1993, Cell.
[67] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[68] W. Kaelin,et al. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. , 2011, Cold Spring Harbor symposia on quantitative biology.
[69] R. Weichselbaum,et al. Predictors of competing mortality in advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] D. Hardie,et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. , 2005, Cell metabolism.
[71] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.